Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Shares Issued (2017 - 2025)

Historic Shares Issued for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $583000.0.

  • Denali Therapeutics' Shares Issued changed N/A to $583000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 9896.12%. This contributed to the annual value of $499.3 million for FY2024, which is 270164.42% up from last year.
  • Denali Therapeutics' Shares Issued amounted to $583000.0 in Q3 2025.
  • Denali Therapeutics' Shares Issued's 5-year high stood at $499.3 million during Q1 2024, with a 5-year trough of $583000.0 in Q3 2025.
  • Moreover, its 5-year median value for Shares Issued was $4.2 million (2022), whereas its average is $52.4 million.
  • Per our database at Business Quant, Denali Therapeutics' Shares Issued soared by 3102549.88% in 2024 and then tumbled by 9988.08% in 2025.
  • Over the past 5 years, Denali Therapeutics' Shares Issued (Quarter) stood at $5.2 million in 2021, then surged by 5418.5% to $285.2 million in 2022, then crashed by 98.35% to $4.7 million in 2023, then soared by 10511.12% to $499.3 million in 2024, then crashed by 99.88% to $583000.0 in 2025.
  • Its Shares Issued was $583000.0 in Q3 2025, compared to $4.1 million in Q2 2025 and $595000.0 in Q1 2025.